Latest period
−$8.85M
YoY change
-19.8%
5Y CAGR
—
Peak year (2006)
−$2.11M
Latest annual
−$28.39M
Operating Cash Flow history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: −$28.39M
Operating Cash Flow growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: -19.8%
Operating Cash Flow history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| 2025 | −$28.39M | -19.8% | +$7.01M | ||
| 2024 | −$35.40M | +12.7% | −$3.99M | ||
| 2023 | −$31.41M | +31.9% | −$7.60M | ||
| 2022 | −$23.81M | -8.5% | +$2.21M | ||
| 2021 | −$26.02M | +149.8% | −$15.60M | ||
| 2020 | −$10.42M | -41.0% | +$7.23M | ||
| 2019 | −$17.64M | -42.0% | +$12.78M | ||
| 2018 | −$30.42M | +176.8% | −$19.43M | ||
| 2017 | −$10.99M | -75.5% | +$33.93M | ||
| 2016 | −$44.91M | -6.7% | +$3.25M | ||
| 2015 | −$48.16M | +12.3% | −$5.29M | ||
| 2014 | −$42.87M | +48.3% | −$13.96M | ||
| 2013 | −$28.91M | +37.9% | −$7.95M | ||
| 2012 | −$20.96M | +42.9% | −$6.29M | ||
| 2011 | −$14.67M | +43.0% | −$4.41M | ||
| 2010 | −$10.26M | -12.8% | +$1.51M | ||
| 2009 | −$11.77M | +24.8% | −$2.34M | ||
| 2008 | −$9.43M | +55.9% | −$3.38M | ||
| 2007 | −$6.05M | +186.3% | −$3.94M | ||
| 2006 | −$2.11M | — | — |
- 2025−$28.39M-19.8%
- 2024−$35.40M+12.7%
- 2023−$31.41M+31.9%
- 2022−$23.81M-8.5%
- 2021−$26.02M+149.8%
- 2020−$10.42M-41.0%
- 2019−$17.64M-42.0%
- 2018−$30.42M+176.8%
- 2017−$10.99M-75.5%
- 2016−$44.91M-6.7%
- 2015−$48.16M+12.3%
- 2014−$42.87M+48.3%
- 2013−$28.91M+37.9%
- 2012−$20.96M+42.9%
- 2011−$14.67M+43.0%
- 2010−$10.26M-12.8%
- 2009−$11.77M+24.8%
- 2008−$9.43M+55.9%
- 2007−$6.05M+186.3%
- 2006−$2.11M—
Operating Cash Flow values are taken from SELLAS Life Sciences Group's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at SELLAS Life Sciences Group (SLS)
Operating Cash Flow for SELLAS Life Sciences Group (SLS): headline value −$8.85M · YoY -19.8%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
SELLAS Life Sciences Group (SLS) most recent annual operating cash flow stands at −$28.39M (2025) – declined 19.8% year-over-year.
The record annual operating cash flow stands at −$2.11M, reached in 2006; the historical low of −$48.16M was recorded in 2015.
SELLAS Life Sciences Group Operating Cash Flow by Year
SELLAS Life Sciences Group Operating Cash Flow 2025: −$28.39M
2025's operating cash flow for SELLAS Life Sciences Group came in at −$28.39M, declined 19.8% below 2024.
SELLAS Life Sciences Group Operating Cash Flow 2024: −$35.40M
SELLAS Life Sciences Group posted operating cash flow of −$35.40M in 2024, grew 12.7% from 2023.
SELLAS Life Sciences Group Operating Cash Flow 2023: −$31.41M
In 2023, SELLAS Life Sciences Group reported operating cash flow of −$31.41M, surged 31.9% from 2022.
SELLAS Life Sciences Group Operating Cash Flow 2022: −$23.81M
SELLAS Life Sciences Group operating cash flow in 2022 was −$23.81M, declined 8.5% below 2021.
SELLAS Life Sciences Group Operating Cash Flow 2021: −$26.02M
SELLAS Life Sciences Group operating cash flow in 2021 was −$26.02M.
See more financial history for SELLAS Life Sciences Group (SLS).
Sector peers by Operating Cash Flow
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation